Nasdaq IPOs

Updated on Monday, April 20, 2020. One biotech IPO is scheduled for the week ahead, and pipeline activity indicates that a few more may be on the way.ORIC Pharmaceuticals (ORIC), a Phase 1 biotech developing small molecule therapies for treatment resistant cancers, plans to

No IPOs are scheduled for the week ahead, though pipeline activity indicates that some may be on the way. Three out of the four IPOs since the second week of March have been biotechs, the sole exception being Chinese AR software company Wimi Hologram Cloud (WIMI). Oncology biotec

There were no IPOs this past week, but initial filings from a biotech and a Chinese issuer are keeping the IPO market moving. After another strong week, the IPO Index is now up about 35% from its March lows. As we pointed out in our 1Q20 IPO Review, the first IPOs to emerge from

There were no IPOs this past week, but initial filings from a biotech and a Chinese issuer are keeping the IPO market moving. After another strong week, the IPO Index is now up about 35% from its March lows. As we pointed out in our 1Q20 IPO Review, the first IPOs to emerge from

Kingsoft Cloud Holdings, a Chinese cloud services and infrastructure provider being spun out of Kingsoft, filed on Friday with the SEC to raise up to $100 million in an initial public offering. Kingsoft Cloud is part of Chinese software franchise Kingsoft Group and is the th

In early April, a short seller accused Chinese coffee chain Luckin (LK) of massively overstating revenues. A day later Chinese education provider TAL reported a non-material overstatement of revenues by an errant employee. Are these two instances leading indicators of financ

Lantern Pharma, a clinical stage oncology biotech using machine learning for drug discovery, filed on Thursday with the SEC to raise up to $29 million in an initial public offering. The company's AI platform, RADR, allows Lantern Pharma to identify potential therapies which were

Luckin Coffee's (LK) alleged financial fraud and decline from an investor favorite to a penny stock is only the tip of the iceberg for the generally poor performance and Western investor skepticism of Chinese IPOs.The latest in a series of setbacks  Even before the specter o

There are no IPOs scheduled for the week ahead.The most likely April IPOs Despite the encouraging market rally this past week, the Renaissance IPO Volatility Index is still about double the five-year average and few companies have filed, indicating the IPO market’s slow Apr

Another biotech IPO has beaten the market blues. Keros Therapeutics (KROS) finished the week up 35%, affirming that the biotech industry won’t be deterred by current market volatility. Oncology biotech Keros Therapeutics priced its upsized IPO at the high end to raise $96 m

Another biotech IPO has beaten the market blues. Keros Therapeutics (KROS) popped 26% on its first day of trading, affirming that the biotech industry won’t be deterred by current market conditions. Oncology biotech Keros Therapeutics priced its upsized IPO at the high end

For years, the VC community bashed the IPO market and its public investors as being too myopic and tied to old-fashioned metrics to appreciate the inflated valuations of giant technology unicorns in which the VCs had invested billions.

For years, the VC community bashed the IPO market and its public investors as being too myopic and tied to old-fashioned metrics to appreciate the inflated valuations of giant technology unicorns in which the VCs had invested billions.

Keros Therapeutics, a Phase 1 biotech developing therapies for blood and musculoskeletal disorders, raised $96 million by offering 6.0 million shares at $16, the high end of the range of $14 to $16. Keros upsized its offering by 1.0 million shares (20%). Keros Therapeutics plans

To Prosperity Technology, which provides auto loan services for ridesharing drivers in Sichuan, China, withdrew its plans for an initial public offering on Tuesday. It originally filed in May 2019 with a proposed deal size of $8 million. The Sichuan, China-based company was found

Allegro Merger, a blank check company formed by Crescendo Partners' Eric Rosenfeld, announced that it and TGI Fridays have terminated their merger agreement.

Biotechs are back as another early stage biotech, Keros Therapeutics (KROS), plans to take on the IPO market in the week ahead, following last week's successful debut of Zentalis Pharmaceuticals (ZNTL). Keros Therapeutics, a Phase 1 biotech developing novel treatments f

Biotechs are back as another early stage biotech, Keros Therapeutics (KROS), plans to take on the IPO market in the week ahead, following last week's successful debut of Zentalis Pharmaceuticals (ZNTL). Keros Therapeutics, a Phase 1 biotech developing novel treatments f

Biotechs are back as another early stage biotech plans to take on the IPO market in the week ahead, following Zentalis Pharmaceuticals' (ZNTL) successful public debut last week. Keros Therapeutics (KROS), a Phase 1 biotech developing novel treatments for hematological and musculo

The biotech industry refuses to wait. This past week saw the first IPOs since the coronavirus outbreak seized the US economy, with oncology biotech Zentalis Pharmaceuticals (ZNTL) up 29% on its first day. The IPO Index slid 8% this week, while the VIX Volatility Index is still at